


## THE CLAIMS


A listing of the claims are as follows.

1. (Previously Presented) An anthraquinone compound of the general formula I or a salt thereof



I

in which  $R^1$  is at the 4 position and is selected from the group consisting of H,  $-NHR^0N(R^5)_2$  in which  $R^0$  is a  $C_{1-12}$  alkanediyl and each  $R^5$  is H or optionally substituted  $C_{1-4}$  alkyl, and a group of formula II




(II)

in which at least one of  $R^6$ ,  $R^7$  and  $R^8$  is selected from  $X^2$ , and  $X^2$  substituted  $C_{1-4}$  alkyl and any others are H or  $C_{1-4}$  alkyl;  $R^9$  is selected from H,  $C_{1-4}$  alkyl,  $X^2$  and  $X^2$  substituted  $C_{1-4}$  alkyl;

$m$  is 0 or 1;

$n$  is 1 or 2;

$R^2$  is at the 1 position and is selected from H,  $-NHR^0N(R^5)_2$  in which  $R^0$  is a  $C_{1-12}$  alkanediyl and each  $R^5$  is H or optionally substituted  $C_{1-4}$  alkyl, and a group of formula II



in which at least one of  $R^6$ ,  $R^7$  and  $R^8$  is selected from  $X^2$ , and  $X^2$  substituted  $C_{1-4}$  alkyl and any others are H or  $C_{1-4}$  alkyl;  $R^9$  is selected from H,  $C_{1-4}$  alkyl,  $X^2$  and  $X^2$  substituted  $C_{1-4}$  alkyl;

$m$  is 0 or 1;

$n$  is 1 or 2;

$R^3$  is at the 5 position and is H or OH;

$R^4$  is at the 8 position and is H or OH;

$X^2$  is a halogen atom, a hydroxyl group, an aryloxy group or an acyloxy group or another nucleofugal leaving group;

provided that at least one of  $R^1$  or  $R^2$  is a group of formula II.

2. (Original) A compound according to claim 1 in which  $R^1$  and  $R^2$  are each a group of formula II.

3. (Original) A compound according to claim 1 in which  $R^1$  is a group of formula II and  $R^2$  is  $NHR^0N(R^5)_2$ .

4. (Original) A compound according to claim 3 in which each  $R^5$  is the same and is H or  $CH_3$ .

5-6. (Canceled)

7. (Previously Presented ) A compound according to claim 1 in which  $R^3$  and  $R^4$  are both hydroxyl.

8. (Original) A compound according to claim 6 in which  $R^3$  and  $R^4$  are both H.
9. (Previously Presented) A compound according to claim 1, in which m is 1.
10. (Previously Presented) A compound according to claim 1, in which m is 0.
11. (Previously Presented) A compound according to claim 1, in which n is 2.
12. (Previously Presented) A compound according to claim 1, in which  $X^2$  is a halogen atom or a nucleofugal leaving group.
13. (Original) A compound according to claim 12, in which  $X^2$  is chlorine.
14. (Previously Presented) A compound according to claim 1, in which either
- i)  $R^6$  is  $CH_2X^3$  and  $R^7$  is H; or
  - ii)  $R^6$  is H and  $R^7$  is  $X^3$ .
15. (Original) A compound according to claim 14 in which  $R^6$  is  $CH_2X^3$  and  $R^7$  is H.
16. (Original) A compound according to claim 15 in which n is 2 and  $R^9$  is  $CH_2X^3$  in which  $X^3$  is the same as  $X^3$  in  $R^6$ .
17. (Canceled)
18. (Previously Presented) A composition comprising a compound according to claim 9 and an excipient.
19. (Original) A composition according to claim 18 which is a pharmaceutical composition and in which the excipient is a pharmaceutically acceptable excipient.

20-39. (Canceled)

40. (Previously Presented) A composition comprising a compound according to claim 12 and an excipient.

41-43. (Canceled)

44. (Previously Presented) A compound selected from the group consisting of:

1- {[ (2-Dimethylamino)ethyl]amino }-4- {[ 2-(3-hydroxypiperidin-1-yl)ethyl]amino }-anthracene-9,10-dione;

1,4-Bis- {[ 2-(3-hydroxypiperidin-1-yl)ethyl]-amino }-anthracene-9,10-dione;

1,4-Bis- {[ 2-(3-hydroxymethylpiperidine-1-yl)ethyl]amino }-5,8-dihydroxy-anthracene-9,10-dione;

1,4-Bis- {[ 2-(3-hydroxymethylpiperidine-1-yl)ethyl]amino }-anthracene-9,10-dione;

1- [(2-Dimethylamino)ethylamino]-4- [2-(3-hydroxymethyl-piperidin-1-yl)ethylamino]-5,8-dihydroxy-anthracene-9,10-dione;

1- [(2-Dimethylamino)ethylamino]-4- [2-(3-hydroxypiperidin-1-yl)-ethylamino]-5,8-dihydroxy-anthracene-9,10-dione;

1,4-Bis- {[ 2-(2-hydroxymethylpiperidin-1-yl)ethyl]amino }-5,8-dihydroxy-anthracene-9,10-dione;

1- {[ (2-Dimethylamino)ethyl]amino }-4- {[ 2-(2-hydroxymethylpyrrolidin-1-yl)ethyl]amino }-5,8-dihydroxy-anthracene-9,10-dione;

1- {[ (2-Dimethylamino)ethyl]amino }-4- {[ 2-(4-hydroxypiperidin-1-yl)ethyl]amino }-anthracene-9,10-dione;

1,4-Bis- {[ 2-(3-hydroxypyrrolidin-1-yl)ethyl]amino }-5,8-dihydroxy-anthracene-9,10-dione;

1,4-Bis- {[ 2-(4-hydroxypiperidin-1-yl)ethyl]amino }-5,8-dihydroxy-anthracene-9,10-dione;

1- {[ (2-Dimethylamino)ethyl]amino }-4- {[ 2-(4-hydroxypyrrolidin-1-yl)ethyl]amino }-5,8-dihydroxy-anthracene-9,10-dione;

1- {[2-(2-Dimethylamino)ethyl]amino}-4- {[2-(2-hydroxymethylpiperidin-1-yl)ethyl]amino}-5,8-dihydroxyanthracene-9,10-dione;

1,4-Bis- {[2-(2-hydroxymethylpyrrolidin-1-yl)ethyl]amino}-5,8-dihydroxyanthracene-9,10-dione;

1- {[2-(2,6-Dihydroxymethylpiperidin-1-yl)ethyl]amino}-4- {[2-(2-Dimethylamino)ethyl]amino}-5,8-dihydroxyanthracene-9,10-dione; and  
1- {[2-(2-Hydroxymethylpyrrolidin-1-yl)ethyl]amino}-anthracene-9,10-dione.

45. (Previously Presented) A compound selected from the group consisting of:

1- {[2-(3-Chloropiperidin-1-yl)ethyl]amino}-4- {[2-(2-dimethylamino)ethyl]amino}-5,8-dihydroxyanthracene-9,10-dione;

1- {[2-(4-Chloropiperidin-1-yl)ethyl]amino}-4- {[2-(2-dimethylamino)ethyl]amino}-5,8-dihydroxyanthracene-9,10-dione;

1- {[2-(2-Chloromethylpyrrolidin-1-yl)ethyl]-amino}-4- {[2-(2-Dimethylamino)ethyl] amino}- 5,8-dihydroxyanthracene-9,10-dione;

1- {[2-(3-Chloropyrrolidin-1-yl)ethyl]amino}-4- {[2-(2-dimethylamino)ethyl]amino}-5,8-dihydroxyanthracene-9,10-dione;

1- {[2-(3-Chloropiperidin-1-yl)ethyl]amino}-4- {[2-(2-dimethylamino)ethyl]amino}-anthracene-9,10-dione;

1- {[2-(2-Chloromethylpiperidin-1-yl)ethyl]amino}-4- {[2-(2-dimethylamino)ethyl]amino}-5,8-dihydroxyanthracene-9,10-dione;

1- {[2-(2-Chloromethylpiperidin-1-yl)ethyl]-(amino)-4- {[2-(2-dimethylamino)ethyl]amino}-5,8-dihydroxyanthracene-9,10-dione;

1- {[2-(2,6-Dichloromethylpiperidin-1-yl)ethyl]-amino}-4- {[2-(2-dimethylamino)ethyl]amino}-5,8-dihydroxyanthracene-9,10-dione; and

1- {[2-(2-chloromethylpyrrolidin-1-yl)ethyl]amino}-anthracene-9,10-dione.

46. (Previously Presented) A compound selected from the group consisting of:

1,4-Bis- {[2-(2-chloromethylpyrrolidin-1-yl)ethyl]amino}-5,8-dihydroxyanthracene-9,10-dione;

1,4-Bis- {[2-(3-chloromethylpiperidin-1-yl)ethyl]amino}-anthracene-9,10-dione;

1,4-Bis- {[2-(3-chloromethylpiperidin-1-yl)ethyl]amino}-5,8-dihydroxyanthracene-9,10-dione; and

1,4-Bis- {[2-(2-chloromethylpiperidin-1-yl)ethyl]amino}-5,8-dihydroxyanthracene-9,10-dione.

47. (Previously Presented) The compound:

1- {[2-(2-Hydroxymethylpyrrolidin-1-yl)-*N*-oxide)ethyl]amino}-4- {[2-(dimethylamino)-*N*-oxide)ethyl]amino}-5,8-dihydroxy-anthracene-9,10-dione.

48. (Previously Presented) A compound selected from the group consisting of:

1- {[2-(3-Chloropiperidin-1-yl)-*N*-oxide)ethyl]amino}-4- {[2-(dimethylamino)-*N*-oxide)ethyl]amino}-5,8-dihydroxyanthracene-9,10-dione;

1- {[2-(4-Chloropiperidin-1-yl)-*N*-oxide)ethyl]amino}-4- {[2-(dimethylamino)-*N*-oxide)ethyl]amino}-5,8-dihydroxyanthracene-9,10-dione; and

1- {[2-(2-Chloromethylpyrrolidin-1-yl)-*N*-oxide)ethyl]amino}-4- {[2-(dimethylamino)-*N*-oxide)ethyl]amino}-5,8-dihydroxyanthracene-9,10-dione.

49. (Previously Presented) The compound:

1,4-Bis- {[2-(2-chloromethylpiperidin-1-yl)-*N*-oxide)ethyl]amino}-5,8-dihydroxyanthracene-9,10-dione.

50. (Previously Presented) A composition comprising a compound and an excipient, wherein the compound is according to claim 10.